Drugs / Tiselizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06704555 | Dec 2024 → Dec 2025 overdue | follicular lymphoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tiselizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06704555 ↗ |
| Route | Intravenous | “200 mg iv day 1” NCT06704555 ↗ |